OMNICELL Reports Total Revenue of $299 Million and Net Income of $3.4 Million for Q2 FY2023
August 7, 2023
🌥️Earnings Overview
For the second quarter of FY2023, ending on June 30 2023, OMNICELL ($NASDAQ:OMCL) reported total revenue of USD 299.0 million, representing a 9.8% decrease from the same period of the previous year. The company also saw a 62.0% decrease in net income, coming in at USD 3.4 million.
Share Price
On Tuesday, OMNICELL reported total revenue of $299 million and net income of $3.4 million for Q2 of the fiscal year 2023. In response to this news, the stock opened at $63.0 and closed at $61.7, down by 2.3% from the previous closing price of 63.2. This marks the second quarter in a row in which OMNICELL has reported net income growth and increased total revenue. The company continues to benefit from favorable market conditions, which have allowed it to make efficient use of its resources and expand its customer base.
Furthermore, the company has maintained their focus on providing quality customer service, which has helped to drive customer satisfaction and build a loyal customer base. OMNICELL looks to continue their streak of successful quarters as they strive to maintain their competitive edge in the industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Omnicell. More…
| Total Revenues | Net Income | Net Margin |
| 1.24k | -23.18 | -1.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. More…
| Operations | Investing | Financing |
| 189 | -61.58 | 20.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.19k | 1.03k | 25.34 |
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.9% | 26.3% | -2.8% |
| FCF Margin | ROE | ROA |
| 10.3% | -1.9% | -1.0% |
Analysis
At GoodWhale, we recently conducted an analysis of Omnicell‘s wellbeing. We found that, based on our Risk Rating, Omnicell is a high risk investment in terms of financial and business aspects. We identified four main risk warnings during our analysis. These findings were uncovered in the income sheet, balance sheet, cashflow statement and non-financial documents. To find out more details and understand the full scope of these risks, become a registered user and check out our analysis for yourself. We hope that this information will help you make an informed decision when it comes to your investments. Good luck! More…
Peers
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
– Nexus AG ($LTS:0FGL)
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
– 10x Genomics Inc ($NASDAQ:TXG)
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
Summary
Investors should take note of OMNICELL‘s second quarter of FY2023 results, showing a 9.8% decrease in revenue and 62.0% decrease in net income compared to the same period the prior year. Despite total revenue of USD 299.0 million, net income was only USD 3.4 million, signaling a potential decline in the company’s performance. Investors should carefully monitor the company’s financials and performance in the next quarters to identify if its business is returning to growth or further decline.
Related Posts
Recent Posts
